立方制药：子公司取得洛索洛芬钠口服溶液药品注册证书

Core Viewpoint - The announcement highlights that Lianfang Pharmaceutical's subsidiary Chengzhi Biological has received approval from the National Medical Products Administration for the drug registration certificate of Loxoprofen Sodium Oral Solution, indicating a significant advancement in the company's product portfolio [1] Group 1 - Loxoprofen Sodium is classified as a non-steroidal anti-inflammatory drug (NSAID) belonging to the phenylpropionic acid class [1] - The drug is noted for its effective analgesic, anti-inflammatory, and antipyretic properties, with a particularly strong analgesic effect [1]